Side effects are not one-size-fits-all
GLP-1 based medications include different products, doses, and uses. Side effects can vary with the specific medication, the treatment stage, a recent dose escalation, other medicines, and individual health factors. A symptom that begins during treatment is worth noticing, but it does not automatically mean the medication caused it.
This guide is broad by design. It can help you sort a symptom into a clearer next question, but it cannot diagnose the cause, determine how urgent it is for you, or replace advice from the clinician who knows your health history and prescription.
Common side effects
Digestive symptoms are among the most commonly reported effects with FDA-approved GLP-1 based weight-loss medications. Across current FDA prescribing information for Wegovy and Zepbound, commonly reported adverse reactions include nausea, vomiting, diarrhea, constipation, abdominal pain or discomfort, indigestion or reflux-related symptoms, fatigue, and, in some products, headache and other effects. The exact side-effect profile differs by medication.
Common does not mean irrelevant. Notice what is happening, how long it lasts, whether it is improving or worsening, and whether it is affecting food, fluids, sleep, work, or daily activity. Those details give a prescribing clinician or pharmacist a much clearer starting point.
For a deeper look at a single concern, see the site’s guides to semaglutide fatigue, semaglutide constipation, and when vomiting needs a call. They can help you prepare questions, not determine the cause of your symptoms.
When to contact your care team
Contact the clinician who prescribes your medication when a symptom is persistent, worsening, severe enough to interfere with normal eating or drinking, or simply does not feel manageable. That includes nausea, vomiting, diarrhea, constipation, abdominal discomfort, reflux symptoms, headache, or fatigue that is not settling or is changing your ability to function.
New or worsening vision changes also deserve prompt contact with the care team, especially for people with type 2 diabetes or a history of diabetic eye disease. FDA labeling for Wegovy and Zepbound includes diabetic retinopathy complications among precautions for patients with type 2 diabetes, and MedlinePlus advises reporting vision changes during treatment.
Other reasons for a timely call include a new neck lump or swelling, persistent hoarseness, or trouble swallowing. These symptoms have many possible causes, but FDA patient counseling information identifies them as symptoms to report to a healthcare provider.
Urgent evaluation
Some symptoms should not wait for an ordinary follow-up.
Seek urgent medical evaluation for severe or persistent abdominal pain, especially pain that may spread to the back, with or without vomiting. FDA labeling identifies acute pancreatitis as a clinically important risk, and MedlinePlus lists ongoing severe stomach pain among symptoms that need prompt medical attention.
Prompt medical evaluation is also appropriate for symptoms that may suggest a gallbladder problem, such as significant upper abdominal pain, fever, yellowing of the skin or eyes, or pale/clay-colored stools.
Persistent vomiting or diarrhea can lead to dehydration and kidney problems. If fluids will not stay down, urination is markedly reduced, you feel faint or severely lightheaded, or symptoms are becoming more intense, seek prompt medical attention rather than trying to manage through guesswork.
Call 911 or seek emergency care for trouble breathing or swallowing, fainting, or swelling of the face, eyes, mouth, tongue, or throat. These can be signs of a serious allergic reaction.
Why timing can matter
Digestive side effects may be more noticeable when treatment is being adjusted. In Zepbound clinical trials, the majority of nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time. That pattern can be useful context, but it is not a reason to dismiss symptoms that are severe, persistent, or concerning.
Write down the medication name, when the symptom started, whether there was a recent treatment change, what you have been able to eat or drink, and any related symptoms such as pain, fever, dizziness, rash, or changes in urination. This is not about proving a cause. It is about giving the care team useful information.
Keep medication decisions with the prescriber
General online information cannot tell you what to do with your specific prescription. Do not increase, decrease, skip, stop, restart, or otherwise change a prescribed medication based on an article or social-media advice. Contact the prescribing clinician or dispensing pharmacist for instructions that apply to your medication, symptoms, and health circumstances.
Anthony Colón, RN provides general education to help people ask clearer questions. This guide does not diagnose a condition, prescribe medication, establish a nurse-patient relationship, or determine whether a treatment is appropriate for an individual.
Authoritative sources
FDA prescribing information: Wegovy, semaglutide, current label accessed September 8, 2026.
FDA prescribing information: Zepbound, tirzepatide, current label accessed September 8, 2026.
MedlinePlus drug information: Semaglutide injection, National Library of Medicine.
MedlinePlus drug information: Tirzepatide injection, National Library of Medicine.
This guide provides general educational information and does not provide medical diagnosis, treatment, or individualized medical advice. Medication and treatment decisions should be made with an appropriately licensed healthcare professional. If you believe you are having a medical emergency, call 911 or seek emergency medical care.